News & Events

Apr 4, 2013
Joint Venture Agreement with Mor Research Applications
Feb 25, 2013
Publication - Comparative Efficacy of Commercially Available and Emerging Antimicrobial Urinary Catheters Against Bacteriuria Caused by E. coli In Vitro.
Jul 10, 2012
Enox Granted TTA License to Wound Care Applications
Apr 25, 2012
Enox Present at IN3 Medical Device 360° Conference
Mar 1, 2012
Enox Present at IN360 Investment in Innovation Conference
Aug 24, 2011
Nitric oxide embedded in polymers for antimicrobial devices - PlasticsToday
Aug 22, 2011
Enox Will be Granted Its Foundation Patent.
Aug 9, 2011
Enox Comparative Study Published In UROLOGY
June 22, 2011
Enox Present At IN3 East Investment In Innovation Conference.
June 13, 2011
Enox Will be Granted a Patent
May 31, 2011
Enox Expands its Technologies to Cover the Wound Care Market.
Feb 22, 2011
Enox Present At IN3 West Investment In Innovation Conference.
Jan 7, 2011
Enox Present At One Med Forum Emerging Company Finance Conference.
Jan 5, 2011
Enox Grants Ortho Dental Solutions LTD License for the Treatment of Periodontal Disease
Jan 4, 2011
Enox Biopharma, Inc. Appoints Dr. John Rewcastle As CEO
Nov 16, 2010
Enox appoints Michael L. Sabolinski, M.D. to its Scientific Advisory Board
Aug 25, 2010
Enox appoints Prof. Asher Tal to its Medical Advisory Board
January 5, 2010
Enox Biopharma, Inc. Announces Publication of Scientific Discoveries
September 12, 2009
Enox Biopharma, Inc to Present at the 49th ICAAC
July 29, 2009
Mr. Itamar David, was appointed as Chief Financial Officer.

Enox Biopharma

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer based medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox’s technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of nosocomial infections the financial burden of infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.

Infection Rates and Treatment Costs

In U.S., one out of every 20 hospital patients (5%) contract a hospital-acquired infection during their stay, leading to approximately 2 million infections, 100,000 deaths and between $28.4 billion and $45 billion in annual costs1,2. European countries report HAI rates between 5-10% with similar impact. The problem is becoming especially acute due to the high correlation between HAIs and increasing antimicrobial resistance to many common antibiotic drugs. More than half of HAIs can be attributed to the use of medical devices, including endotracheal tubes, urinary catheters, central venous catheters, and various other implants. Once these infections occur, they can cascade leading to acute respiratory distress syndrome, kidney failure, shock sepsis and even death.



1
Gerencher, K. April 2008. The CDC and The fight against Hospital-Acquired infection.
2Scott RD Direct Medical Costs of Healthcare Associated Infections in US Hospitals and the Benefits of Prevention. Centers for Disease Control and Prevention, March 2009